This is a proof of concept study to determine the safety of subconjunctival aflibercept injection, an anti-vascular endothelial growth factor (VEGF) medication, in the treatment of recalcitrant pseudophakic cystoid macular edema (CME)
Inclusion Criteria
- Diagnosed with pseudophakis CME defined as:
- Central retinal thickness (CRT) > 300 microns
- Presence of intraretinal cysts on optical coherence tomography (OCT)
- Visual acuity ≥ 20/32 with petaloid leakage on fluorescein angiogram and late leakage at the disc
- Diagnosed with "recalcitrant" CME, defined as less than a 15% decrease in CRT after at least 6 weeks of topical non-steroidal anti-inflammatory drug
- Has had cataract surgery in the study eye with posterior chamber or anterior chamber intraocular lens implementation
Exclusion Criteria
- Retinal diseases (including diabetic retinopathy, retinal vein or artery occlusion, neovascular age-related macular degeneration, radiation retinopathy)
- Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye
- Active infect5ious conjunctivitis, keratitis, scleritis or endophtalmitis in either eye
Study Requirements
Participation will be approximately 6 months with 8 visits if criteria is met to continue with treatment at the monthly 1 visit. If subjects no allowed to continue with treatment they would complete 3 study visits.
